Work

Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”

Year: 2020

Type: letter

Abstract: We appreciate Dr. Taylor’s thorough review of the history of dipeptidyl peptidase-4 (DPP4) activity measurements. Although dilution of sitagliptin could account for the slightly diminished inhibition of DPP4 activity in controls compared with that previously reported, it could not account for the difference between controls and obese hypertensives reported in the paper, as DPP4 activity was measured using the same methodology in all groups. In addition, we reported an inverse correlation between body mass index and DPP4 activity, suggesting the effect may have been related to the volume of distribution of sitagliptin. dipeptidyl peptidase-4 Financial Support: This work was supported by National Institutes of Health (NIH) Grants T32GM007569 (to J.R.W.), F31DK108444 (to M.M.S.), and R01HL125426 (to N.J.B.); American Heart Association (AHA) Grant 17SFRN33520017; and Grant K23HL119602 NIH/NHLBI (to J.K.D.). This work was also supported by Clinical and Translational Science Award (CTSA) Grant UL2TR000445 (National Institutes of Health). Disclosure Summary: The authors have nothing to disclose.

Source: Journal of the Endocrine Society

DOI: 10.1210/jendso/bvaa006

Authors: Jessica R Wilson, Megan M Shuey, Nancy J Brown, Jessica K Devin

Institutions: Vanderbilt University, University of Pennsylvania, Vanderbilt University Medical Center, University of Colorado Health, UCHealth Yampa Valley Medical Center

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,255